CeriBell (NASDAQ:CBLL - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of CeriBell in a research note issued to investors on Wednesday, November 13th. William Blair analyst M. Andrew expects that the company will earn ($0.28) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for CeriBell's current full-year earnings is ($1.55) per share. William Blair also issued estimates for CeriBell's Q2 2026 earnings at ($0.25) EPS and Q3 2026 earnings at ($0.24) EPS.
A number of other analysts also recently issued reports on the company. Bank of America began coverage on CeriBell in a research report on Tuesday, November 5th. They issued a "buy" rating and a $32.00 price target for the company. Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They set a "buy" rating and a $30.00 target price on the stock. JPMorgan Chase & Co. began coverage on CeriBell in a research report on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price objective on the stock. Canaccord Genuity Group boosted their price target on CeriBell from $30.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday. Finally, TD Cowen began coverage on CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $31.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $31.20.
Check Out Our Latest Analysis on CeriBell
CeriBell Stock Performance
CBLL stock traded down $1.02 during midday trading on Friday, reaching $26.53. 108,391 shares of the company traded hands, compared to its average volume of 225,172. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
